EFFECT OF LONG-TERM ENOXAPARIN THERAPY ON RISK OF RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS AND RECANALIZATION OFTHROMBOSED VEINS
https://doi.org/10.21518/2307-1109-2015-2-39-50
Abstract
The article presents the results of its own study of the effect of long-term (not less than 30 days) enoxa-parin therapy (1 mg/kg administered subcutaneously every 12h) on the risk of recurrent venous thromboembolic complications (VTC) and recanalization of thrombosed deep veins. The enoxaparin therapy was compared with a standard approach to treatment (unfractionated heparin for not less than 5 days followed by the administration of warfarin). The extended enoxaparin therapy was significantly more effective than standard treatment due to its impact on the risk of recurrent deep vein thrombosis (DVT) and recanalization of thrombosed deep veins. On top of that, the effect of enoxaparin in the first month of treatment of VTC episodes last for the next 11 months. As a result, the extension of enoxaparin therapy was associated with an 88% reduction in the risk of DVT recurrence during 12 months of anticoagulant therapy and a 2.5-fold increase in the probability of recanalization of venous occlusions by the end of the first year of treatment compared with the standard therapy with unfractionated heparin and warfarin.
About the Authors
N. M. Vorobyova
Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, 2GBOU VPO
Russian Federation
Russian Federation
O. V. Ermolina
Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, 2GBOU VPO
Russian Federation
Russian Federation
T. V. Balakhonova
Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, 2GBOU VPO
Russian Federation
Russian Federation
A. I. Kiriyenko
N.I. Pirogov Russian National Research Medical University, the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
E. P. Panchenko
Russian Cardiology Research and Production Complex FGBU of the Ministry of Health of the Russian Federation, 2GBOU VPO
Russian Federation
Russian Federation
References
1. Spencer FA, Emery C, Lessard D et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.J GenInternMed, 2006. 21: 722-727.
2. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet, 2012. 379: 1835-1846.
3. Christiansen SC, Cannegieter SC, Koster T et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events.JAMA, 2005. 293: 2352-2361.
4. Kahn SR, Schrier I, Julian JA. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med, 2008. 149: 698-707.
5. Douketis JD, Gu CS, Schulman S et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med, 2007.147: 766-774.
6. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. NEnglJMed, 2004. 350: 2257-2264.
7. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010.4 (1): 37 с.
8. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). EurHeartJ, 2014. 35: 3033-3080.
9. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141 (Suppl): e419S-e494S.
10. Воробьева Н.М., Панченко Е.П., Кириенко А.И. и др. Варфарин или эноксапарин: что назначить больному венозным тромбозом в первый месяц лечения? Терапевтический архив, 2009.81 (9): 57-61.
11. Воробьева Н.М., Панченко Е.П., Добровольский А.Б. и др. Улучшение реканализации глубоких вен и «исходы» венозных тромбоэмболических осложнений при продленной терапии эноксапарином. Ангиология и сосудистая хирургия, 2011. 17 (1): 87-94.
12. Воробьева Н.М., Панченко Е.П., Ермолина О.В. и др. Продление терапии эноксапарином до одного месяца способствует реканализации окклюзивно тромбированных глубоких вен. Терапевтический архив, 2011. 83(8): 33-37.
13. Vorobyeva NM, Panchenko EP, Kirienko AI et al. Prolongation of enoxaparin therapy to one month facilitates restoration of blood flow and improves 1-year outcomes in patients with venous thromboembolism. Eur HeartJ, 2010. 31 (Suppl. 1): 979.
14. Vorobyeva N, Panchenko E, Ermolina O et al. Prolongation of enoxaparin therapy to one month improves recanalization of occlusive thrombosed deep veins. Thrombosis Research, 2014. 133 (Suppl. 3): S66.
15. Воробьева Н.М., Добровольский А.Б., Титаева Е.В. и др. Практические аспекты продления терапии эноксапарином до одного месяца в амбулаторных условиях у больных венозными тромбоэмбо-лическими осложнениями. Атеротромбоз, 2014. 1: 33-43.
16. Воробьева Н.М., Панченко Е.П. Антикоагулянтная терапия венозных тромбоэмболических осложнений: проблемы и перспективы. Российский кардиологический журнал, 2015. 3 (119): 7-17.
17. Ninet J, Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of DVT. A collaborative European multicentre study. Thromb Haemost, 1991. 65: 251-255.
18. Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular-weight heparin compared with continuous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch InternMed, 1993. 153: 1541-1546.
19. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for prevention of recurrent venous thromboembolism in patient with cancer. NEnglJMed, 2003. 349: 146-153.
20. Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. AmJMed, 2006. 119: 1062-1072.
21. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch InternMed, 2002. 162: 1729-1735.
22. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEnglJMed, 2009. 361: 2342-2352.
23. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation, 2014. 129: 764-772.
24. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. NEnglJ Med, 2010. 363:2499-2510.
25. The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. NEnglJMed, 2012. 366: 1287-1297.
26. Agnelli G, Buller HR, Cohen A et al. AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. NEnglJMed, 2013.369:799-808.
27. Воробьева Н.М., Панченко Е.П. Новые пероральные антикоагулянты и ацетилсалициловая кислота в лечении венозных тромбо-эмболических осложнений. Атеротромбоз, 2013.1:53-64.
28. Воробьева Н.М., Панченко Е.П. Дабигатрана этексилат — новый пероральный антикоагулянт для лечения венозных тромбоэм-болических осложнений. Атеротромбоз, 2014. 1: 50-58.
29. Воробьева Н.М. Особенности применения рива-роксабана у больных венозными тромбоэмболи-ческими осложнениями. Медицинский алфавит, 2014. 3(219): 28-34.
30. Воробьева Н.М., Панченко Е.П. Апиксабан: новые возможности в лечении венозных тромбоэмболических осложнений. Атмосфера. Новости кардиологии, 2015. 2: 10-17.
Review
For citations:
Vorobyova N.M., Ermolina O.V., Balakhonova T.V., Kiriyenko A.I., Panchenko E.P. EFFECT OF LONG-TERM ENOXAPARIN THERAPY ON RISK OF RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS AND RECANALIZATION OFTHROMBOSED VEINS. Aterotromboz = Atherothrombosis. 2015;(2):39-50. (In Russ.) https://doi.org/10.21518/2307-1109-2015-2-39-50
Views:
1145
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 